Description

Retatrutide — Triple Hormone Receptor Agonist

Retatrutide (LY-3437943) is a novel investigational peptide that acts as a triple agonist at GIP, GLP-1, and glucagon receptors. It has been the subject of Phase 2 clinical trials evaluating its effects on obesity and type 2 diabetes, making it one of the most studied compounds in next-generation metabolic research.

Research Applications

Preclinical and early-phase clinical studies have explored Retatrutide for its effects on glucose metabolism, energy expenditure, and lipid regulation. Its unique triple-agonist profile allows researchers to study the synergistic effects of simultaneously activating three key metabolic hormone pathways.

Specifications

• Purity: 99% (HPLC verified)
• Quantity: 10mg per vial
• Form: Lyophilized powder
• Storage: Store at -20°C; protect from light and moisture; reconstituted solution stable at 2–8°C for up to 28 days
• Molecular Weight: ~4,813 g/mol

For laboratory and research use only. Not for human consumption.